$EIQ (+1,99 %) Echo IQ is a publicly traded Australian medtech/AI company (ASX: EIQ) specializing in cardiac diagnostic software (EchoSolv HF/AS)The company is in the clinical validation and FDA approval phase (no significant revenue yet), financed through capital increases and interest income from cash reserves.

A capital increase took place recently, and the company is currently rolling out its product in the U.S. As a result, the company is transitioning from a clinical developer to a commercial player.

https://www.boerse-express.com/news/articles/echoiq-aktie-pro-medicus-investiert-10-millionen-aud-926201

The latest figures are from the half-year report in December:

https://api.investi.com.au/api/announcements/eiq/b4443306-1fa.pdf

Brief overview of key figures (comparison of H1 2025/26 vs. H1 2024/25):

Income Statement

• Revenue: 90,909 AUD (previous year: 101,409 AUD)
• Other income (primarily interest): 299,809 AUD (previous year: 172,345 AUD)
• Loss after taxes: AUD 8,659,669 (prior year: AUD 6,215,645) – loss increased significantly
• Major cost drivers: Personnel expenses of 2,578,557 AUD, equity-based compensation of 2,883,442 AUD, consulting and professional fees of 1,619,637 AUD
• Loss per share: -1.34 cents (prior year: -1.09 cents)

Balance Sheet (as of Dec. 31, 2025 vs. June 30, 2025)

• Cash and cash equivalents: AUD 11,212,499 (vs. AUD 6,617,702) – increase
• Time deposits/deposits: AUD 2,000,000 (vs. AUD 11,518,288) – significant decrease (maturity realized)
• Intangible assets: 4,416,654 AUD (vs. 4,686,945 AUD)
• Total assets: 17,988,519 AUD (vs. 23,372,338 AUD)
• Total Liabilities: 718,606 AUD (vs. 615,414 AUD) – minimal, no financial liabilities
• Equity (net assets): 17,269,913 AUD (vs. 22,756,924 AUD) – decrease of approximately 24%

Cash Flow

• Operating cash flow: -5,181,712 AUD (previous year: -3,410,633 AUD) – higher cash outflow
• Investing Activities: +9,491,151 AUD (primarily from the maturity of time deposits)
• Financing activities: +287,735 AUD (capital increase, significantly lower than the previous year’s 6.64 million AUD)
• Cash and cash equivalents at the end of the period: 11,212,499 AUD (previous year: 5,351,566 AUD)

Four analysts currently rate the stock as a “Strong Buy.”

10 million AUD flowed in from the partnership $PME (-1,15 %) —in which some members of this community have invested. @Investingyoung
@thewolfofxetra

Another 10 million AUD is expected to be provided following FDA approval.

Does anyone in the community know this company and have an opinion? Perhaps a volatile bet for our @Multibagger ?

Hello, friends of the sun! After my absence, I now have a gem of a software program from Australia for you.

Since I’m really not much of a writer, I’ve created a YouTube channel for all kinds of stock market content, including analyses of growth companies and hidden champions.

I’d appreciate your support and feedback (in the YouTube comments).

$PME (-1,15 %)

https://youtu.be/QaJ60udZIHQ?si=STvjN5j6QyZT_F22

$PME (-1,15 %) new addition to the depot!

Key growth figures (FY 2025)

• Turnover: AUD 213.0 million (+31.9% year-on-year).
• Net profit (after tax): AUD 115.2 million (+39.2%).
• EBIT (operating profit): AUD 157.7 million (+40.5%).
• Dividend: AUD 0.30 per share (+37.5%).
• EBIT margin: 74.0% (increase from 69.5% in the previous year).
• Net margin: Approx. 54 %.
• Return on equity (ROE): Over 60%, underlining the extremely efficient use of capital.

The first tranche into the zone is in, now with $4519 (-2,29 %) and $HIMS (+0,29 %) now 3 stocks in the healthcare sector

for all those who are now interested in the share and are also buying:

Please pay attention to the spread, buy between 7;30-8:00 then it is extreme (over 6%)

had a spread of 1.x%, which is ok for an Australian small cap

Those who work with Pro Medicus $PME (-1,15 %) yet, you should definitely do so! The Australian software company offers innovative solutions for medical imaging and data management and convinces with a highly profitable Software-as-a-Service (SaaS) model.

🔍 The business model at a glance:

✅ Visage imaging platform

• Core solution: "Visage 7", a cloud-based PACS software for managing and analyzing medical images (CT, MRI, X-ray).
• Pay-per-use modelRevenue is generated per examined image or scan.

✅ Long-term SaaS contracts

• Cooperation with leading clinics, especially in the USA.
• Contracts with terms of 5-7 years provide for stable, recurring sales.

✅ Cloud-first approach

• Hosting via Google Cloud or AWSwhich means customers do not need their own servers.
• Scalable and cost-efficient.

✅ High margins & premium customers

• Gross margin of 70-77 % thanks to low variable costs.
• Focus on high-priced radiology centers & university hospitals.

✅ Growth through expansion & innovation

• Expansion in the USA & Europe, increased use of AI-supported diagnostic tools.

📊 Fundamental key figures (10-year growth per year):

📈 Turnover: +28,11 %

💰 Dividend: +37,02 %

💵 Cash flow: +40,14 %

💸 Profit: +43,18 %

🏦 Financial strength & dividend outlook

• Debt is fully covered by core assets and could be repaid in around one year.
• High cash position enables investments in future technologies or the repurchase of further share packages
• Current dividend yield: 0.16but strong growth potential - analysts forecast a personal dividend yield of personal dividend yield of 7.75 % by 2040.

⚡ Conclusion:

Pro Medicus $PME (-1,15 %) stands for growth, innovation and financial strength. The company has established itself as a leading provider in the field of medical imaging & AI-supported diagnostics and and convinces through a scalable, highly profitable business model with with recurring revenues.

Disclaimer:

This analysis is for for information purposes only and does not constitute does not constitute investment advice or a recommendation to buy/sell for financial instruments. It is not an invitation to trade in securities. Historical performance is not an not an indicator of future results. Investments in securities involve risks and should be carefully considered.